These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 28654545)

  • 21. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
    Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
    Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Independent prognostic factors for posttransplant survival in hepatocellular carcinoma patients undergoing liver transplantation.
    Xing M; Kim HS
    Cancer Med; 2017 Jan; 6(1):26-35. PubMed ID: 27860456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loco-regional therapy in patients with Milan Criteria-compliant hepatocellular carcinoma and short waitlist time to transplant: an outcome analysis.
    Sourianarayanane A; El-Gazzaz G; Sanabria JR; Menon KV; Quintini C; Hashimoto K; Kelly D; Eghtesad B; Miller C; Fung J; Aucejo F
    HPB (Oxford); 2012 May; 14(5):325-32. PubMed ID: 22487070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
    J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
    Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
    Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of salvage liver transplantation.
    Guerrini GP; Gerunda GE; Montalti R; Ballarin R; Cautero N; De Ruvo N; Spaggiari M; Di Benedetto F
    Liver Int; 2014 Jul; 34(6):e96-e104. PubMed ID: 24517642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States.
    Kwong AJ; Ghaziani TT; Yao F; Sze D; Mannalithara A; Mehta N
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1142-1150.e4. PubMed ID: 34358718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
    Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
    Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria.
    Ciccarelli O; Lai Q; Goffette P; Finet P; De Reyck C; Roggen F; Sempoux C; Doffagne E; Reding R; Lerut J
    Transpl Int; 2012 Aug; 25(8):867-75. PubMed ID: 22716073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma.
    Habibollahi P; Hunt S; Bitterman T; Gade TP; Soulen MC; Nadolski G
    Diagn Interv Radiol; 2018 Jul; 24(4):213-218. PubMed ID: 30091712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
    Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
    Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.
    Kornberg A; Witt U; Matevossian E; Küpper B; Assfalg V; Drzezga A; Hüser N; Wildgruber M; Friess H
    PLoS One; 2013; 8(1):e53960. PubMed ID: 23349774
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation.
    Oligane HC; Xing M; Kim HS
    Radiology; 2017 Mar; 282(3):869-879. PubMed ID: 27673508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation.
    Guerrini GP; Pinelli D; Di Benedetto F; Marini E; Corno V; Guizzetti M; Aluffi A; Zambelli M; Fagiuoli S; Lucà MG; Lucianetti A; Colledan M
    Surg Oncol; 2016 Dec; 25(4):419-428. PubMed ID: 26403621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
    Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
    J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.